701. An Open-label Phase 2a Study of Ibezapolstat, a Unique Gram-positive Selective Spectrum (GPSS) Antibiotic, for Patients with Clostridioides difficile Infection

BACKGROUND: Ibezapolstat, a DNA polymerase IIIC inhibitor, currently in Phase 2 clinical development for treatment of C. difficile infection (CDI). Its unique mechanism of action targets low G+C content Gram-positive bacteria primarily Firmicutes including C. difficile. Phase I healthy volunteer res...

Descripción completa

Detalles Bibliográficos
Autores principales: Garey, Kevin W, Begum, Khurshida, Hu, Chenlin, Wang, Weiqun, Lancaster, Chris, Gonzales-Luna, Anne J, Loveall, Caroline, Jahangir Alam, M, Silverman, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643934/
http://dx.doi.org/10.1093/ofid/ofab466.898

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643934/
http://dx.doi.org/10.1093/ofid/ofab466.898

Ejemplares similares